MichaelMorrisMD

Genitourinary Oncology

Member, Memorial Sloan Kettering Cancer Center Professor, Medicine, Weill Cornell Medical College

Overview of Dr. Morris

Dr. Michael Morris is an oncologist in New York, NY and is affiliated with Memorial Sloan-Kettering Cancer Center. He received his medical degree from Icahn School of Medicine at Mount Sinai and has been in practice 23 years. He specializes in genitourinary oncology and his clinical and research focus is on high risk, recurrent, and metastatic prostate cancer, regarding drug, imaging, and biomarker development.

Office
Memorial Sloan Kettering Cancer Center New York
1275 York Avenue
New York, NY 10021
Book by Phone+1(617) 440-3228
Is this information wrong?

Education & Training

Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 1997 - 2000
New York Presbyterian Hospital (Columbia Campus)Residency, Internal Medicine, 1994 - 1997
Icahn School of Medicine at Mount SinaiClass of 1994

Certifications & Licensure

FL State Medical License 2021 - Present
NJ State Medical License 2019 - 2025
NY State Medical License 1996 - 2025
American Board of Internal Medicine Medical Oncology

Clinical Trials

Calcitriol and Zoledronate in Treating Patients With Progressive Prostate Cancer Start of enrollment: 1999 Oct 01
Completed
Phase 1
Testosterone in Treating Patients With Progressive Prostate Cancer That No Longer Responds to Hormone Therapy Start of enrollment: 2000 Feb 01
Completed
Phase 1
Monoclonal Antibody Therapy in Treating Patients With Prostate Cancer Start of enrollment: 2001 Jun 01
Completed
Phase 2
Ixabepilone With or Without Estramustine in Treating Patients With Progressive Prostate Cancer Start of enrollment: 2001 Jul 01
Completed
Phase 1, Phase 2
Study of Samarium Sm-153 Lexidronam Combined With Docetaxel for Patients With Prostate Cancer Start of enrollment: 2005 Jul 01
Unknown status
Phase 1, Phase 2
[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer Start of enrollment: 2003 Feb 01
Recruiting
Not Applicable
Alpharadin™ (Radium-223 Chloride) Safety and Dosimetry With HRPC That Has Metastasized to the Skeleton Start of enrollment: 2008 Aug 01
Completed
Phase 1
Exogenous Testosterone Plus Dutasteride for the Treatment of Castrate Metastatic Prostate Cancer Start of enrollment: 2009 Mar 01
Completed
Phase 2
Tesetaxel in Chemotherapy-naive Patients With Progressive, Castration-resistant Prostate Cancer Start of enrollment: 2011 Feb 01
Unknown status
Phase 2
Sodium Fluoride (NaF) Positron Emission Tomography/Computed Tomography (PET/CT) in Patients With Metastatic Castrate-resistant Prostate Cancer (CRPC) With Microtubule Directed Chemo or AR-directed Therapy Start of enrollment: 2011 Nov 01
Completed
Observational Longitudinal Study of Pain in Men With Metastatic Castrate-Resistant Prostate Cancer Start of enrollment: 2012 Jun 01
Withdrawn
Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer Start of enrollment: 2014 Jan 22
Active, not recruiting
Phase 3
Use of an Experimental Radiopharmaceutical (131I-MIP-1095) in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Start of enrollment: 2017 Jan 19
Completed
Phase 1
A Study to Test Radium-223 With Docetaxel in Patients With Prostate Cancer Start of enrollment: 2018 Jun 19
Recruiting
Phase 3
Safety and Targeting of Anti-hk2 Antibody in mCRPC Start of enrollment: 2019 Sep 18
Terminated
Early Phase 1
A Study of Stereotactic Body Radiation Therapy and Radium (Ra-223) Dichloride in Prostate Cancer That Has Spread to the Bones Start of enrollment: 2021 Nov 12
Recruiting
Phase 2
Roles: Contact
Safety Study of a Radiolabeled Antibody (7E11) in Patients With Progressive Hormone Refractory Prostate Cancer Start of enrollment: 2007 Feb 01
Unknown status
Phase 1
Roles: Contact, Principal Investigator
Join now to see all

Publications & Presentations

PubMed

The Lancet Commission on prostate cancer: planning for the surge in cases.
Nicholas D James, Ian Tannock, James N'Dow, Felix Feng, Silke Gillessen, Syed Adnan Ali, Blanca Trujillo, Bissan Al-Lazikani, Gerhardt Attard, Freddie Bray, Eva Compér...> ;Lancet. 2024 Apr 4
Radiographic Progression-Free Survival and Clinical Progression-Free Survival as Potential Surrogates for Overall Survival in Men With Metastatic Hormone-Sensitive Pro...
Susan Halabi, Akash Roy, Larysa Rydzewska, Siyuan Guo, Peter Godolphin, Maha Hussain, Catherine Tangen, Ian Thompson, Wanling Xie, Michael A Carducci, Matthew R Smith,...> ;Journal of Clinical Oncology. 2024 Mar 20
Phase I Study of ORIC-101, a Glucocorticoid Receptor Antagonist, in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Prog...
Wassim Abida, Andrew W Hahn, Neal Shore, Neeraj Agarwal, Paul Sieber, Matthew R Smith, Tanya Dorff, Paul Monk, Matthew Rettig, Rupal Patel, Anne Page, Maureen Duff, Ro...> ;Clinical Cancer Research. 2024 Mar 15
Pharmacogenetic and clinical risk factors for bevacizumab-related gastrointestinal hemorrhage in prostate cancer patients treated on CALGB 90401 (Alliance).
Jai N Patel, Chen Jiang, Kouros Owzar, Daniel L Hertz, Janey Wang, Flora A Mulkey, William K Kelly, Susan Halabi, Yoichi Furukawa, Cameron Lassiter, Susan G Dorsey, Pa...> ;The Pharmacogenomics Journal. 2024 Mar 4
Prognostic and predictive analyses of circulating plasma biomarkers in men with metastatic castration resistant prostate cancer treated with docetaxel/prednisone with ...
Andrew B Nixon, Yingmiao Liu, Qian Yang, Bin Luo, Mark D Starr, John C Brady, Wm Kevin Kelly, Himisha Beltran, Michael J Morris, Daniel J George, Andrew J Armstrong, S...> ;Prostate Cancer and Prostatic Diseases. 2024 Feb 12
Design Considerations in the PSMAfore Trial.
Oliver Sartor, Karim Fizazi, Ken Herrmann, Michael J Morris> ;Journal of Nuclear Medicine. 2024 Feb 1
PRESTO: A Phase III, Open-Label Study of Intensification of Androgen Blockade in Patients With High-Risk Biochemically Relapsed Castration-Sensitive Prostate Cancer (A...
Rahul Aggarwal, Glenn Heller, David W Hillman, Han Xiao, Joel Picus, Mary-Ellen Taplin, Tanya Dorff, Leonard Appleman, Douglas Weckstein, Akash Patnaik, Alan Bryce, Da...> ;Journal of Clinical Oncology. 2024 Apr 1
First-in-human imaging with [Zr]Zr-DFO-SC16.56 anti-DLL3 antibody in patients with high-grade neuroendocrine tumors of the lung and prostate.
Tendler, S., Dunphy, M., Agee, M., O'Donoghue, J., Aly, R., Choudhury, N., Kesner, A., Kirov, A., Mauguen, A., Baine, M., Schoder, H., Weber, W., Rekhtman, N., Lyashch...> ;Medrxiv. 2024 Jan 11
Costs to Medicare of Nonrecommended Bone-Modifying Agent Use for Castration-Sensitive Prostate Cancer.
Nemirovsky, D., Mishra Meza, A., Chakraborty, N., Persaud, S., Mitchell, A., Farooki, A., Morris, M.> ;JCO Oncology Practice. 2024 Mar 1
Evaluating Immune-Related Adverse Events Using PRO-CTCAE in a Phase II Study of Ipilimumab for Hormone-Sensitive Prostate Cancer.
de Almeida, D., Cohn, E., Baser, R., Anderson, J., Danila, D., Morris, M., Slovin, S., Abida, W., Scher, H., Autio, K.> ;Journal of Immunotherapy and Precision Oncology. 2023 Nov 1
Physician knowledge, practice patterns, and barriers encountered regarding guideline-concordant use of bone modifying agents for prostate cancer.
Aaron P Mitchell, Sonia Persaud, Paul Palyca, Andrew Salner, Azeez Farooki, Jamie S Ostroff, Michael J Morris, Susan Chimonas> ;The Prostate. 2024 Feb 1
2 citations
Molecular features of prostate cancer after neoadjuvant therapy in the phase 3 CALGB 90203 trial.
Takayuki Sumiyoshi, Xiaofei Wang, Evan W Warner, Andrea Sboner, Matti Annala, Michael Sigouros, Kevin Beja, Kei Mizuno, Shengyu Ku, Ladan Fazli, James Eastham, Mary-El...> ;Journal of the National Cancer Institute. 2024 Jan 10
3 citations
SNMMI Consensus Statement on Patient Selection and Appropriate Use ofLu-PSMA-617 Radionuclide Therapy.
Thomas A Hope, Emmanuel S Antonarakis, Lisa Bodei, Jeremie Calais, Amir Iravani, Heather Jacene, Phillip J Koo, Alicia K Morgans, Joseph R Osborne, Scott T Tagawa, Mar...> ;Journal of Nuclear Medicine. 2023 Sep 1
9 citations
Health-related quality of life and pain outcomes with [Lu]Lu-PSMA-617 plus standard of care versus standard of care in patients with metastatic castration-resistant pr...
Karim Fizazi, Ken Herrmann, Bernd J Krause, Kambiz Rahbar, Kim N Chi, Michael J Morris, Oliver Sartor, Scott T Tagawa, Ayse T Kendi, Nicholas Vogelzang, Jeremie Calais...> ;The Lancet. Oncology. 2023 Jun 1
2 citations
Identification of incidental brain tumors in prostate cancer patients via PSMA PET/CT.
Lily A McLaughlin, Onur Yildirim, Marc K Rosenblum, Brandon S Imber, Justin M Haseltine, Michael J Zelefsky, Heiko Schöder, Michael J Morris, William M Rafelson, Simon...> ;Journal of Neuro-Oncology. 2023 Jun 1
24 citations
Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conferenc...
Sharifi, N., Silke Gillessen, Alberto Bossi, Ian D Davis, Johann de Bono, Karim Fizazi, Nicholas D James, Nicolas Mottet, Neal Shore, Eric Small, Matthew Smith, Christ...> ;European Journal of Cancer. 2023 May 1
36 citations
Second Version of the Prostate Cancer Molecular Imaging Standardized Evaluation Framework Including Response Evaluation for Clinical Trials (PROMISE V2).
Robert Seifert, Louise Emmett, Steven P Rowe, Ken Herrmann, Boris Hadaschik, Jeremie Calais, Frederik L Giesel, Robert Reiter, Tobias Maurer, Matthias Heck, Andrei Gaf...> ;European Urology. 2023 May 1
8 citations
PARP Inhibitors for Prostate Cancer: Tangled up in PROfound and PROpel (and TALAPRO-2) Blues.
Nick Beije, Wassim Abida, Emmanuel S Antonarakis, Elena Castro, Ronald de Wit, Karim Fizazi, Silke Gillessen, Maha Hussain, Joaquin Mateo, Michael J Morris, David Olmo...> ;European Urology. 2023 Sep 1
Looking at the Future of Prostate Cancer Treatment: A Conversation Between Michael Morris, Jeremie Calais, and Johannes Czernin.
Michael J Morris, Jeremie Calais, Johannes Czernin> ;Journal of Nuclear Medicine. 2023 May 1
External Validation of a Prognostic Model of Overall Survival in Men With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer.
Susan Halabi, Qian Yang, Akash Roy, Bin Luo, John C Araujo, Christopher Logothetis, Cora N Sternberg, Andrew J Armstrong, Michael A Carducci, Kim N Chi, Johann S de Bo...> ;Journal of Clinical Oncology. 2023 May 20
2 citations
Reply to Timothée Olivier, Kerrington Powell, Vinay Prasad. Lutetium-177-PSMA-617 in Metastatic Castration-resistant Prostate Cancer: Limitations of the VISION Trial. ...
Michael J Morris, Oliver Sartor, Johann S de Bono, Karim Fizazi, Scott T Tagawa> ;European Urology. 2023 Jul 1
3 citations
Randomized Phase III Study of Enzalutamide Compared With Enzalutamide Plus Abiraterone for Metastatic Castration-Resistant Prostate Cancer (Alliance A031201 Trial).
Michael J Morris, Glenn Heller, David W Hillman, Olivia Bobek, Charles Ryan, Emmanuel S Antonarakis, Alan H Bryce, Olwen Hahn, Himisha Beltran, Andrew J Armstrong, Law...> ;Journal of Clinical Oncology. 2023 Jun 20
1 citations
Clinical Impact of a Rapid Genetic Testing Model for Advanced Prostate Cancer Patients.
Kelsey E Breen, Heather Symecko, Kelsey Spielman, Rebecca Gebert, Ibrahim H Shah, Stacy Pundock, Melissa Batson, Vivek K Narayan, Zsofia K Stadler, Karen A Autio, Wass...> ;The Journal of Urology. 2023 May 1
34 citations
Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal T...
Silke Gillessen, Alberto Bossi, Ian D Davis, Johann de Bono, Karim Fizazi, Nicholas D James, Nicolas Mottet, Neal Shore, Eric Small, Mathew Smith, Christopher Sweeney,...> ;European Urology. 2023 Mar 1
2 citations
From Concept to Regulatory Drug Approval: Lessons for Theranostics.
Marlon Perera, Michael J Morris> ;Journal of Nuclear Medicine. 2022 Dec 1
Join now to see all

Lectures

Diagnostic performance of 18F-DCFPyL in the OSPREY Trial: A prospective phase 2/3 multicenter study of 18F-DCFPyL PET/CT imaging in patients (Pts) with known or suspec...
2019 ASCO Annual Meeting - 6/1/2019

Press Mentions

Transforming Cancer Clinical Trials for Better, Faster ResultsApril 14th, 2023
PSMA PET Academy - Case Discussion: PSMA for Biochemical Recurrence and SRT Planning: Early Biochemical Relapse in Patients - Jeremie Calais, Michael Morris, & Alberto BrigantiMarch 17th, 2023
NIH Awards $23 Million for Telehealth OncologyAugust 30th, 2022
Join now to see all

Professional Memberships

American Society of Clinical Oncology - ASCO
Member

Hospital Affiliations

Memorial Sloan Kettering Cancer CenterNew York, New York

Insurance Accepted

Aetna Choice POS II
Aetna HMO
BCBS Blue Card PPO
CIGNA HMO
CIGNA Open Access
CIGNA PPO
Empire BCBS HMO
Empire BCBS PPO
Great West PPO
Humana ChoiceCare Network PPO
Multiplan PHCS PPO
Multiplan PPO
MVP Healthcare PPO
Oxford Health Freedom
Oxford Health Liberty
QualCare HMO
QualCare PPO
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO
Please verify your coverage with the provider's office directly when scheduling an appointment